Glenmark USA settles antitrust case with Humana for USD 15.28 million

Regulatory & Legal View source PDF Explain this filing

GLENMARK · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.1%Reaction day

₹2282.00

prior close

₹2276.00

announcement price

After-mkt

timing

Nifty Midcap 150market+0.3%-0.1% vs market

Pharmaceuticals peers, median of 165sector-0.6%+0.7% vs sector

On the reaction day the stock moved 0.1 pts less than Nifty Midcap 150 and 0.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.6

15m

+1.0

30m

+1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.1+0.3-0.1-0.6+0.7

Next day

+1.7+0.3+1.3-0.3+2.0

+1.6-0.2+1.8-0.7+2.3

+2.1-0.0+2.1-1.4+3.5

+1.0-0.4+1.4-1.1+2.1

-1.6-0.7-0.9-2.0+0.4

+1.6-0.2+1.8-1.4+3.0

15d

+8.2-1.5+9.6-1.0+9.1

+3.9-4.7+8.6-0.4+4.3

+0.0-7.8+7.9-3.2+3.3

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Glenmark's US subsidiary has agreed to settle antitrust litigation with Humana for USD 15.28 million, payable in two installments. The case, consolidated in the Eastern District of Pennsylvania, alleged price-fixing of generic drugs. Glenmark denies all allegations and the settlement is not an admission of liability. The full amount was already provisioned in the financials and will not materially impact the company's financial position.

Likely market impact

Neutral; amount already provisioned in books, no admission of wrongdoing. Limited effect on shareholders.